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Abstract
Introduction: Scale-up of HIV self-testing (HIVST) will play a key role in meeting the United Nation’s 90-90-90 targets.
Delayed re-reading of used HIVST devices has been used by early implementation studies to validate the performance of self-
test kits and to estimate HIV positivity among self-testers. We investigated the stability of results on used devices under con-
trolled conditions to assess its potential as a quality assurance approach for HIVST scale-up.
Methods: 444 OraQuick® HIV-1/2 rapid antibody tests were conducted using commercial plasma from two HIV-positive
donors and HIV-negative plasma (high-reactive n = 148, weak-reactive n = 148 and non-reactive n = 148) and incubated
them for six months under four conditions (combinations of high and low temperatures and humidity). Devices were re-
read daily for one week, weekly for one subsequent month and then once a month by independent readers unaware of
the previous results. We used multistage transition models to investigate rates of change in device results, and between
storage conditions.
Results and discussion: There was a high incidence of device instability. Forty-three (29%) of 148 initially non-reactive results
became false weak-reactive results. These changes were observed across all incubation conditions, the earliest on Day 4
(n = 9 kits). No initially HIV-reactive results changed to a non-reactive result. There were no significant associations between
storage conditions and hazard of results transition. We observed substantial statistical agreement between independent re-
readers over time (agreement range: 0.74 to 0.96).
Conclusions: Delayed re-reading of used OraQuick® HIV-1/2 rapid antibody tests is not currently a valid methodological
approach to quality assurance and monitoring as we observed a high incidence (29%) of true non-reactive tests changing to
false weak-reactive and therefore its use may overestimate true HIV positivity.
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1 | INTRODUCTION
HIV self-testing (HIVST) is being scaled-up using a variety of
distribution models throughout Africa, the Americas, Asia and
Europe [1-4]. No clear monitoring and evaluation or external
quality assurance (EQA) systems exist for HIVST devices and
this raises concern for national reference laboratories, regula-
tors and policymakers [5-7].
While previous studies report acceptable sensitivity and
specificity when HIVST is conducted by intended users [8,9],
it is unclear whether this will be maintained once HIVST pro-
grammes are implemented at scale. Observation and in-depth
interviews reveal that without a demonstration, operator
errors are common in both conducting and interpreting self-
tests [10,11]. Scale-up will have to be accompanied by a
robust quality assurance system.
A reactive HIVST indicates that HIV antibodies are present
in the oral or fingerstick/blood sample of the user. Further
testing to confirm a positive diagnosis following linkage to
care acts as an active system for detecting false-reactive
results and ensures individuals are not incorrectly started on
antiretroviral therapy (ART). In most contexts, however, the
prevalence of false-reactive results prior to ART clinic enrol-
ment (whether or not individuals came from HIVST) is not
tracked and rates of linkage remain highly variable and can be
very low without active support [12-14]. Self-testers with
non-reactive results, unless linking to voluntary male medical
circumcision or pre-exposure prophylaxis services, would not
typically seek or receive further testing and confirmation,
meaning a false non-reactive result would not be detected.
Methods that detect incorrect results and misinterpretation
are required for individual care as well as for quality
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assurance. One approach, which has been utilized in early
HIVST implementation studies, is for self-testers to return
used devices for delayed re-reading by trained staff in parallel
with self-reported interpretation of results [15,16]. However,
delays between device use and re-reading, and environmental
storage conditions during this period could impair the validity
of this method. We therefore set out to investigate the stabil-
ity of OraQuick® HIV-1/2 rapid antibody test (OraQuick HIV)
results with delayed re-reading stored under controlled incu-
bation conditions for prolonged periods. We selected the Ora-
Quick® HIV-1/2 rapid antibody test kit, which is the same
product (in different packaging) as the OraQuick® HIV Self-
Test which is prequalified by the World Health Organization
(WHO) [17].
2 | METHODS
2.1 | Materials and equipment
Two different batches (HIVCO-4308 and HIVCO-4309) of
OraQuick® HIV-1/2 rapid antibody test kits (assembled in
Thailand for OraSure Technologies, Inc. Bethlehem, PA, USA)
were obtained from the manufacturer. Human HIV serocon-
version panel plasma samples from two donors (Donor No.
73695 panel number 12007-08 and 09, [18] and 75018 panel
number 9077-24 and 25 [19]) were purchased from Zepto-
Metrix Corporation (Buffalo, NY, USA). Human plasma nega-
tive for HIV, hepatitis B, C, E and syphilis was purchased from
the National Blood Service (Liverpool, UK).
2.2 | Sample preparation
The OraQuick® HIV-1/2 Rapid Antibody Test is WHO pre-
qualified for use with oral fluid, whole blood, serum or plasma.
The matrix of the sample (i.e. plasma rather than an oral
crevicular fluid sample) was not a crucial factor in this investi-
gation, as we were not investigating specificity or sensitivity.
What was important was the basis of the immuno-chromato-
graphic stability of the test. The use of HIV antibody-positive
and -negative plasma allowed us to investigate this.
Four panel samples from two donors were combined to
produce an HIV-reactive “mini-pool” of stock serum. This was
checked to ensure the correct result and intensity of test line
on the OraQuick HIV device. From this stock, an HIV-reactive
sample was prepared with the addition of HIV-negative
plasma (1:8 dilution factor). An HIV weak-reactive sample was
prepared with a 1:16 dilution factor.
2.3 | Sample size calculation
To estimate sample size, we assumed that 0.2% of all used tests
would change over six months. To estimate accuracy of rate of
change within  1% with 95% confidence, 77 tests were
required to be read for each condition, with a total of four con-
ditions, giving a minimum sample of 308 kits. With available
resources, were able to include more samples (444 total).
2.4 | Conducting the tests
The study was conducted in the laboratory under controlled
conditions rather than using actual patient-used HIVST devices.
This eliminated the risk that the test had not been performed
correctly which could have influenced the study results.
A total of 444 OraQuick HIV tests were conducted in the
laboratory following the manufacturer’s instructions for use
(IFU). Five microlitres of the prepared samples (HIV reactive
n = 148, HIV weak-reactive n = 148 or HIV non-reactive
n = 148) was delivered into the developer solution before
mixing gently. The test device was labelled with an identifica-
tion number on the back and inserted “pad end” into the
developer solution. Devices were read within the 20- to 40-
minute reading window (measured using a digital timer) by
three different laboratorians, trained in the reading of the
devices and blinded to each other’s interpretation.
2.5 | Read definitions/interpretation
On the test device there is a window next to which there is a
letter “T” for test line and a “C” for control line. As per the IFU,
a non-reactive result was recorded when only a single quality
control line was visible adjacent to the letter “C” on the test
device. A weak-reactive was recorded when there were two vis-
ible lines on the test device, the first adjacent to the letter “C”
(control) and the second adjacent to the letter “T” (test) but the
test line was not as intense as the control line. A reactive test
was recorded when both “C” and “T” lines were visible and the
“T” line was at least as intense as the “C” line. An invalid result
was defined as no line present adjacent to the letter “C.”
2.6 | Incubation conditions
Following initial reads, devices were placed in one of four labora-
tory benchtop incubators (Benchmark Scientific), each set to a
different incubation condition: (a) control temperature (30°C)
with high humidity (70%); (b) control temperature (30°C) with
low humidity (20%); (c) high temperature (40°C) with high
humidity (70%); (d) or high temperature (40°C) with low humidity
(20%). Each condition had 37 HIV non-reactive, 37 HIV weak-
reactive and 37 HIV reactive devices allocated to it (Figure 1).
2.7 | Re-reading intervals
Devices were re-read by either two or three blinded and inde-
pendent readers daily for one week, weekly for one subsequent
month and then once a month for the following five months,
giving a total of 13 reads over the 6-month study period
(November 2016 through to April 2017). Each of the laborato-
rians interpreted the test face up, recorded the test result
(check box non-reactive, weak-reactive or reactive) on the data
log sheet and then turned the test over to record the test iden-
tification number along with any additional comments. Data
were input onto a blinded (of previous re-read result) elec-
tronic log. Data were unblinded and analysed after 6 months.
2.8 | Data analysis
Two laboratorians had to be in agreement for a “final” test
result interpretation. We compared agreement between
readers at each time point using the kappa statistic with
bootstrapped 95% confidence intervals for three readers and
Scott’s pi for two readers. To estimate the hazard of transi-
tion between device states (non-reactive, weak-reactive, and
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reactive) over time, and the effects of incubation storage
conditions, we fitted a multistage transition model using a
hidden Markov process. Model fit was evaluated by visually
comparing the fitted hazard function within each condition
over time with observed transition events. In the final model,
terms for piecewise intensities were fitted at Day 1 to 2,
Day 2 to 3; Day 3 to 4; Day 8 to 15; and Day 15 to 181
to account for the high intensity of transition. Analysis was
done using R version 3.3.2 (R Foundation for Statistical Com-
puting, Vienna).
3 | RESULTS AND DISCUSSION
Devices were first read following the manufacturer IFU, after
20 minutes and within 40 minutes of conducting the test
Figure 1. Flow diagram of sample allocation and re-read results over time.
The flow chart shows the allocation of non-reactive, weak reactive and reactive test devices to the four different incubation conditions on Day 0
and the re-read results for Day 0 to Day 161. Changes in non-weak reactives are underlined and highlighted in bold. The first changes observed
“non-reactive” transitioning to “weak reactive” was on Day 4 in the incubation condition of high temperature and low humidity.
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(Day 0) for control purposes. On Day 0, all reactive devices
gave the expected dilution results (reactive or weak-reactive)
and a following masked re-read showed all three independent
readers in agreement (100%). Statistical agreement between
independent readers over the six-month period ranged from
0.70 (95% confidence interval (CI): 0.66 to 0.74) to 0.96 (95%
CI: 0.94 to 0.98) [20].
There was a high incidence of OraQuick HIV result transi-
tion between states over time (Figure 2). A total of 43 of the
148 true non-reactive devices (29%) changed to a false weak-
reactive result with the earliest change observed on Day 4
(n = 9 kits) incubated at high temperature and low humidity
(Figure 1). Transition between states over time was also
observed, with tests changing from true non-reactive to false
weak-reactive and then back to true non-reactive (77
instances out of a total of 1776) and weak-reactive results
changing to strong reactive and then back to weak-reactive
(135 instances). The majority of these true reactive transitions
occurred early (from Day 1) with the greatest intensity of
transition occurring up to Day 15. Transitions continued to
occur throughout the six-month follow-up period. No devices
with an initial reactive result changed to a weak-reactive or
non-reactive result over the six-month period. The test control
line showed 100% stability throughout the study.
Changes occurred across all controlled incubation condi-
tions with the earliest transition from a true non-reactive to a
false weak-reactive occurring under high temperature and low
humidity conditions on Day 4. However, in our final model,
there was no significant association between the incubation
condition under which devices were stored and the hazard of
transition between stages (Table 1).
Our key finding shows the OraQuick HIV device can have a
result change from a true non-reactive to a false weak-reac-
tive result when reading is extended beyond the manufacturer
reading time window. The reasons underlying our finding are
not clear and we did not find any association with different
temperature and humidity conditions. Explanations for the
appearance of the false weak-reactive lines may be due to
nonspecific antibody binding at the HIV antigen test site on
the devices nitrocellulose test strip [21] or nonspecific binding
of protein-A gold conjugate which the test uses as the colori-
metric indicator or perhaps a lateral back flow or “settling
effect” over time and further investigation into these hypothe-
ses is required.
The observed change in result raises concerns over the use
of delayed re-reading of devices for monitoring HIVST inter-
pretation, as well as for programmatic monitoring, evaluation
and EQA. Research studies utilizing delayed re-reading of
returned OraQuick® HIV Self-Test for establishing positivity
may overestimate the true HIV positivity amongst a self-test-
ing population.
A previous study conducted in Malawi examined the pre-
use stability of OraQuick® HIV test kits [16]. 371 optimally
stored and 375 pre-incubated used devices were re-read over
a 12-month period. A 0.2% change from an initial reactive
result to a later non-reactive was observed (one in the pre-
incubated and one in the optimally stored group). These
results suggested that HIVST device results remained stable
over time. However, the focus of this study was its effect on
pre-use storage conditions. Post-use storage conditions were
not rigorously monitored and so cannot be reliable compared
with the results from our study.
Figure 2. Observed transitions between HIV re-read results over the study period.
(A) Decrease in true HIV non-reactive inoculated test devices as they transit to “false” HIV weak reactive. (B) Increase in the number of test
devices re-read as HIV weak reactive. (C) Increase in the number of test devices re-read as reactive which then transition back to weak reactive
over time.
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During this controlled study, our trained laboratorians could
correctly distinguish false weak-reactive test lines from true
weak-reactive test lines as they have a greyish appearance
compared with the pinker true-reactive. Implementation of
this more nuanced approach may however prove challenging
in programmatic settings where previous reports show that
providers struggle to identify and interpret weak reactives
[22] and other factors, such as interferents, and tests used
among people with HIV using ART can cause weak reactives
[23].
In addition to a false weak-reactive line causing uncertainty
to an EQA model, when testing a population, it is likely that
more “true negative” samples will change to “false weak reac-
tive” and delayed re-reading by self-testers themselves could
lead to individual misinterpretation and misunderstandings.
Our study showed that the OraQuick HIV device was stable
up to four days after the sample was applied, suggesting that
the risk of this is low but nevertheless self-testers need clear
messages about the read window and the importance of read-
ing the device according to manufacturer instructions.
A limitation of this study was that on some re-read days
only two individual re-reads were conducted (23%) and there-
fore a third “tie breaker” re-read was not available. The very
nature of self-testing (conducting the test privately at home)
means conventional facility/laboratory-based QA systems of
test devices are eluded, and an alternative approach is
required. Digital photography and immediate re-reading are
two other options that are being further explored for QA dur-
ing HIVST scale-up, but these also have their limitations.
National reference laboratories should play an integral role in
external quality control measures by conducting batch testing
at the actual sites of distribution of HIVST to ensure that the
integrity of the devices is not compromised during transport
and storage.
4 | CONCLUSIONS
The use of re-reading used OraQuick HIVST devices as an
approach to quality assurance and monitoring test results is
not advised. The instability observed in true non-reactive tests
changing to false weak reactive test results in our study
demonstrates that re-reading is not a reliable method to
assess user interpretation of the OraQuick HIVST and mea-
surement of HIV positivity rates among self-testers.
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Table 1. Hazard of transition between HIV test read stage over
six months
Incubation condition
and transition
stage (From ? To)
Hazard ratio for
transition intensity
(vs. cool/dry
incubation
condition)
95% confidence
interval
Cool/humid
HIV non-reactive
? HIV weak-reactive
0.88 0.47 to 1.64
HIV weak-reactive
? HIV non-reactive
0.95 0.33 to 2.71
HIV weak-reactive
? HIV reactive
1.27 0.80 to 2.03
HIV reactive
? HIV weak-reactive
1.41 0.87 to 2.28
Warm/humid
HIV non-reactive
? HIV weak-reactive
0.81 0.43 to 1.56
HIV weak-reactive
? HIV non-reactive
1.27 0.47 to 3.42
HIV weak-reactive
? HIV reactive
0.87 0.53 to 1.44
HIV reactive
? HIV weak-reactive
0.94 0.56 to 1.59
Warm/Dry
HIV non-reactive
? HIV weak-reactive
1.06 0.57 to 1.95
HIV weak-reactive
? HIV non-reactive
1.24 0.46 to 3.35
HIV weak-reactive
? HIV reactive
0.94 0.58 to 1.52
HIV reactive
? HIV weak-reactive
1.15 0.69 to 1.89
Estimated by fitting multistage transition model for each test read con-
dition with hidden Markov process, and with terms for incubation con-
dition and piecewise transition intensities between Day 1 to 2, Day 2
to 3, Day 3 to 4, Day 8 to 15 and Day 15 to 181.
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